Introduction

U
pper urinary tract transitional-cell carcinoma (UT-TCC) is relatively rare and accounts for no more than 5% of all urothelial tumors and less than 10% of renal tumors. 1 For many years, the gold standard in UT-TCC management has been radical nephroureterectomy with excision of the bladder cuff. 2 Advancements in endourologic instrument technology have allowed urologists to manage this malignancy without radical extirpation of the affected kidney and ureter. Current practice patterns reveal that there is no consensus on the management of UT-TCC; however, minimally invasive conservative measures are preferred. 3 Many nephroureterectomies are performed yearly in the United States when, in contrast, most UT-TCC is low grade and superficial. 4 This discordance is difficult to understand when one considers the strong arguments for renal preservation in the management of small renal tumors. 5 The feasibility and success of conservative measures for UT-TCC have been widely published, but there has not been an objective cost analysis performed to date, despite many cost analyses for other urologic conditions. [6] [7] [8] In the era of cost-effective management, we should understand the costs to preserve a kidney in the setting of UT-TCC, especially in patients with imperative indications (bilateral UT-TCC, a solitary kidney, and preexisting renal insufficiency). End-stage renal disease (ESRD) accounts for a large percentage of health care spending in the elderly. 9 Moreover, survival and quality of life when receiving dialysis can be severely diminished. [9] [10] Our goal was to examine the direct costs of renal-sparing conservative measures v radical nephroureterectomy and subsequent chronic kidney disease (CKD) or ESRD. Secondary analysis includes a discussion of survival and quality-of-life issues for both treatment cohorts.
Patients and Methods
We conducted a retrospective review of a selected cohort of patients who were treated at Thomas Jefferson Hospital with conservative renal-sparing ureteroscopic management of UT-TCC and who were followed for a minimum of 2 years. The data were analyzed to determine recurrence rates, progression, renal preservation, and survival. Patients with high-grade disease and=or unresectable disease were offered laparoscopic radical nephroureterectomy with excision of the bladder cuff. The costs per case were based on equipment, anesthesia time, surgeon fees, pathologic evaluation fees, and hospital stay. Additional costs of follow-up office and imaging visits were collected as well.
A standardized protocol was used with regard to uppertract surveillance, which included retrograde pyelography and ureteroscopy at 3-month intervals from last recurrence and extended to 6 months for negative surveillance. Urine cytologic evaluation and imaging was performed at each follow-up office visit.
Global costs for arteriovenous fistula formation, continuous hemodialysis, and medical management of CKD were estimated based on published 2007 cost reports. 9 UT-TCC survival and recurrence data and quality-of-life estimates when receiving dialysis were collected from published papers found on Medline. Cost analysis only included events related to UT-TCC and excluded bladder tumor encounters for all groups. All costs were calculated based on data for U.S. dollars (USD).
Results
From 1996 to 2006, 254 patients were evaluated and treated for UT-TCC at our institution. A cohort of 57 patients was examined who had a minimum follow-up period of 2 years. The average number of procedures per patient was 10.1 with a range of 5 to 41. The patient demographics and treatment results are summarized in Table 1 . A total of eight patients had a solitary renal unit at presentation. Renal preservation in our series approached 81%, with cancer-specific survival of 94.7%.
Cost analysis
Our algorithm for patients in whom UT-TCC was diagnosed is outlined in Figure 1 . The direct costs incurred at Thomas Jefferson Hospital were calculated for ureteroscopic laser treatment, diagnostic ureteroscopy, laparoscopic nephroureterectomy with bladder cuff, and dialysis vascular access formation (Table 2) . Estimates for cadaveric renal transplantation were based on available published data. 11 The cost to maintain a kidney was calculated per annum and projected over a period of 5 years against other treatment options (Table 3, Table 4 , Fig. 2 ). 
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A best-case scenario for an initial treatment and no recurrences yielded an initial cost of $5,270 for ureteroscopic laser treatment followed by a negative surveillance visit at 3 months with subsequent negative surveillance visits that occurred every 6 months, which cost $7,181 annually. A worstcase scenario had UT-TCC recurrence at each follow-up visit, an initial ureteroscopic laser ablation treatment that cost $5,270, followed by re-treatment visits every 3 months costing a total of $20,634 in the first 12 months and $26,864 each subsequent year. This scenario comprises the most aggressive treatment algorithm reserved for patients with imperative indications for renal preservation.
Most patients will fall between these two extremes of estimated 5-year costs for renal preservation in the setting of UT-TCC management. The estimated cost of a recurrence per year is $18,980 USD and adds an additional outpatient hospital visit per year. Therefore, at our institution, with an average recurrence rate of 5.5 recurrences per patient over a mean follow-up period of 53 months, our average cost to maintain a kidney is $117,890 USD.
Under the most-costly scenario, an initial nephroureterectomy cost of $21,764 is followed by a one-time cost of $14,592 for arteriovenous fistula placement and then $69,758 annually for maintenance hemodialysis. Over an estimated 5-year projection, this cost rises to $385,146.
Survival analysis
The overall survival for our cohort of 57 patients was 93% with a cancer-specific survival of 94.7%. Renal preservation was 80.7% in our series. The cancer-specific survival for patients treated with a solitary kidney was 75% (2=8). Four patients were alive at the time of analysis with metastatic TCC and were undergoing medical therapy.
A review of selected UT-TCC series using conservative management was examined for survival data and is summarized in Table 5 . [12] [13] [14] [15] [16] [17] Cancer-specific survival rates ranged from 49.3% to 100% in the selected series. Renal preservation rates ranged from 70% to 80%.
In contrast, survival data for ESRD and hemodialysis are not very impressive. Table 6 summarizes the age-based survival rates for patients on chronic hemodialysis over 1, 3, 5, and 10 years. 9 
Discussion
The challenge of conservative management of UT-TCC is that it requires advanced endoscopic skills, expensive equipment, and compliant patients willing to undergo multiple procedures. In this analysis, the measure of cost was used to objectively compare the conservative management of UT-TCC against nonrenal-sparing measures. Recent data suggest increased risks for renal insufficiency in patients who underwent radical nephrectomy for renal cortical tumors, supporting the importance of renal preservation. 18 The argument for conservative measures in the setting of a solitary kidney, bilateral UT-TCC, and preexisting CKD are not difficult to make when considering the alternative options. This study, however, highlights the importance of renal preservation in patients who were considered elective candidates for conservative (normal contralateral kidney) management. Moreover, there are data to suggest that higher grade tumors develop in patients with ESRD or CKD and UT-TCC and that these patients subsequently fare worse. 19 This fact may be further reflected in our series as well as that of the Mayo clinic. 14 In patients with imperative indications for renal preservation, the cost savings over a 5-year period range from 3-fold to almost 10-fold when compared with the ESRD and hemodialysis cohort. In addition, the overall survival of conservatively treated patients is much higher compared with agebased survival statistics in patients receiving hemodialysis. Survival rates on chronic hemodialysis for a 70-year-old patient with ESRD are 70.6%, 38.8%, and 19.2%, respectively, at 1, 3, and 5 years. In contrast, the worst reported cancerspecific and overall survival for conservative UT-TCC management was 49.3% and 35%, respectively, for a cohort with an average age of 74 years with 35 months of follow-up. 14 Assuming a worst-case scenario of a solitary kidney with recurrences at each follow-up for 5 years v nephroureterectomy and dialysis for the same period, an estimated $252,272 USD would be saved, not to mention improved quality of life and overall survival. These savings would cover the expenses of five cadaveric renal transplantations. Real-world costs are difficult to calculate, especially when you include loss of productivity, morbidity, etc; therefore, this cost analysis is very conservative and underestimates the real cost of preserving a kidney in the setting of UT-TCC.
The issue of quality of life in UT-TCC has never been examined. Performing a MEDLINE search using quality of life and TCC revealed only eight reports regarding bladder TCC and urinary diversions. Using the Medical Outcomes Study Short-Form 36-item survey (SF-36), investigators found that patients with superficial bladder TCC who were undergoing repeated transurethral resections had general health perceptions lower than normal cohorts; however, in patients who were undergoing multiple procedures, the quality-of-life scores for all other domains improved with four or more transurethral resection procedures. 20 This is our best estimate of UT-TCC quality of life. In contrast, a similar MEDLINE search using the terms quality of life and dialysis yielded 1087 published reports. Quality-of-life evaluations in ESRD hemodialysis patients have revealed that patients would give up one-quarter to one-half of their remaining life expectancy in current health if the sacrifice would allow them to have perfect health for a shorter time. 21 
Conclusions
Conservative endoscopic management of UT-TCC in our experience should be the gold standard for low-grade and superficial-stage disease. Not only is cancer-specific and overall survival excellent, but also recurrences and progression are manageable and oncologically acceptable. From a cost perspective, renal-sparing UT-TCC management is effective in reducing ESRD health care expenses.
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